Intero Biosystems is selling lab-grown human intestines to drugmakers as regulators push for alternatives to animal testing, while the startup looks to scale production and expand its organoid technology.
Intero Biosystems is selling lab-grown human intestines to drugmakers as regulators push for alternatives to animal testing, while the startup looks to scale production and expand its organoid technology.
Source: TechCrunch
The founders detailed how their startup is developing AI that can design chips, learn from each iteration, and improve subsequent designs, all with the goal of automating and accelerating the chip design process.
Every day, conversations unfold across social media and websites around the world. A seemingly insignificant post—whether it involves AI-generated misinformation, hate speech, or a damaging rumor—can quickly snowball into a much larger public controversy. Gudea, a company that tracks how stories and rumors spread online that describes itself as the “storm tracker for the internet,” […]
Databases have traditionally been designed either for analytical data or for operational data. But database engine CedarDB supports both, and its approach has gained relevance with the rise of agentic AI.
